Stay updated with breaking news from Solid Biosciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer has a pipeline with more than 90 drugs in development. Pfizer is developing two drugs capable of generating more than a billion sales. Competition is fierce but Pfizer is in the race.
/PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced...
A Duchenne muscular dystrophy drug candidate from Italfarmaco Group has encouraging preliminary data from a pivotal study. The Milan, Italy-based pharmaceutical company says it now plans to meet with U.S. and European authorities about seeking regulatory approval for the small molecule.
A number of firms have modified their ratings and price targets on shares of Solid Biosciences (NASDAQ: SLDB) recently: 5/3/2022 – Solid Biosciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Solid Biosciences LLC is a life science company. It focuses on developing therapies […]